22179-86-8

Basic information

• Product Name: 4-(TRIFLUOROMETHYL)BENZAMIDOXIME
• Synonyms: BUTTPARK 33\04-34;4-TRIFLUOROMETHYLBENZAMIDE OXIME;4-(TRIFLUOROMETHYL)BENZAMIDOXIME;N-HYDROXY-4-TRIFLUOROMETHYLBENZAMIDINE;N'-HYDROXY-4-(TRIFLUOROMETHYL)BENZENECARBOXIMIDAMIDE;4-(Trifluoromethyl)benzamidoxime 97%;4-(Trifluoromethyl)benzamidoxime97%;N'-Hydroxy-4-(trifluoromethyl)benzenecarboximidamide, Tech.
• CAS NO: 22179-86-8
• Molecular Formula: C₈H₇F₃N₂O
• Molecular Weight: 204.15
• Product Categories: pharmacetical
• Mol File: 22179-86-8.mol
• Article Data: 58

Chemical Properties

• Melting Point: 125-130 °C(lit.)
• Boiling Point: 297.106 °C at 760 mmHg
• Flash Point: 133.485 °C
• Appearance: /
• Density: 1.401 g/cm³
• Vapor Pressure: 0.000619mmHg at 25°C
• Refractive Index: 1.499
• PKA: 13.71±0.50(Predicted)
• CAS DataBase Reference: 4-(TRIFLUOROMETHYL)BENZAMIDOXIME(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(TRIFLUOROMETHYL)BENZAMIDOXIME(22179-86-8)
• EPA Substance Registry System: 4-(TRIFLUOROMETHYL)BENZAMIDOXIME(22179-86-8)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36-60-37
• WGK Germany: 3
• Hazardous Substances Data: 22179-86-8(Hazardous Substances Data)

Usage

Uses

4-(Trifluoromethyl)benzamidoxime (N-Hydroxy-4-(trifluoromethyl)benzamidine) may be used to synthesize 5-(3-chlorothiophen-2-yl)-3-(4-trifluoromethylphenyl)-1,2,4-oxadiazole, a potential anticancer agent.

InChI:InChI=1/C8H7F3N2O/c9-8(10,11)6-3-1-5(2-4-6)7(12)13-14/h1-4,14H,(H2,12,13)

Upstream product

• 455-18-5 4-CF₃C₆H₄CN 
• 455-19-6 4-Trifluoromethylbenzaldehyde 
• 66046-34-2 4-(trifluoromethyl)benzaldehyde oxime 
• 402-43-7 p-trifluoromethylphenyl bromide 

Downstream Products

• 480390-86-1 methyl 4-[3-(4-trifluoromethylphenyl)-1,2,4-oxadiazol-5-yl]benzoate 
• 206882-64-6 2-(4-trifluoromethylphenyl)-4-methylpyrimidine 3-oxide 

Relevant articles and documents

Computer-aided identification, synthesis, and biological evaluation of novel inhibitors for botulinum neurotoxin serotype A

Botulinum neurotoxins (BoNTs) are among the most potent biological toxin known to humans, and are classified as Category A bioterrorism agents by the Centers for Disease Control and prevention (CDC). There are seven known BoNT serotypes (A-G) which have b

Synthesis, spectroscopic characterization and DNA/HSA binding studies of (phenyl/naphthyl)ethenyl-substituted 1,3,4-oxadiazolyl-1,2,4-oxadiazoles

Two new series of conjugated arylethenyl-1,3,4-oxadiazolyl-1,2,4-oxadiazoles were obtained and spectroscopically characterized in terms of UV-Vis absorption, fluorescence and interaction with CT-DNA and Human Serum Albumin (HSA) biomolecules. Phenyl- and 1-naphthyl-bearing examples were analysed, and the spectroscopic properties of its substitution series were compared, showing extensive conjugation in all compounds and absorption differences due to both the aryl-ethenyl subunit and substituted phenyl/phenylene at the 1,2,4-oxadiazole side. Strong binding interactions of the obtained compounds with CT-DNA and moderate HSA-association capability were observed spectroscopically, and further docking studies were performed. This journal is

INHIBITOR COMPOUNDS

The disclosure relates to heterocyclic compounds and methods for their preparation. The disclosure provides compounds that may have beneficial therapeutic activity in the treatment of a disease or condition mediated by excessive or otherwise undesirable Des1 and/or fibrotic activity.